TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells
TG101209 是一种新型 JAK2 抑制剂，在多发性骨髓瘤中具有显著的体外活性，并对 CD45+ 骨髓瘤细胞表现出优先细胞毒性
期刊:American Journal of Hematology
影响因子:10.1
doi:10.1002/ajh.21785
Vijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, Michael Timm, Linda Wellik, Timothy Halling, Animesh Pardanani, Ayalew Tefferi, Sundararasan Vincent Rajkumar, Shaji Kumar
免疫
细胞生物学
骨髓瘤
T细胞
FlowCytometry
JAK/STAT
BrdU
